Streetwise Reports' Article Archives — August 2020 back to current month (32)
Aimmune Therapeutics shares traded 170% higher after the company reported it entered into a definitive agreement to be acquired by Nestlé for $34.50 per share in cash.
Revive Therapeutics reported it submitted the clinical protocol for independent Institutional Review Board approval for its Phase 3 study of Bucillamine in COVID-19.
VBI Vaccines shares traded higher after the company reported preclinical coronavirus program data and selection of clinical candidates with potential as one-dose vaccines.
As the Covid pandemic accelerates the adoption of telemedicine technology, Reliq Health Technologies' recent contracts represent exponential growth.
Fluidigm Corp. shares reached a new 52-week high after the firm reported the FDA granted Emergency Use Authorization for saliva-based Advanta Dx SARS-CoV-2 RT-PCR Assay for COVID-19.
CytoDyn Inc. shares traded higher after the company reported it received authorization from the U.K.'s MHRA to proceed with its Phase 3 study of leronlimab in patients with severe-to-critical COVID-19.
Shares of Cryoport Inc. reached a new 52-week high after the company reported it signed an agreement to acquire French firm CRYOPDP in an all cash transaction valued at €49 million.
CureVac NV shares traded 13% higher after the company reported it is in advanced discussions with the European Commission to supply up to 405 million doses of a potential mRNA-based COVID-19 vaccine.
This and other recent key events of AzurRx BioPharma are recapped in a ROTH Capital Partners report.
The deal is summarized and Principia Biopharma's Q2/20 clinical achievements are recapped in an H.C. Wainwright & Co. report.
Shares of Momenta Pharmaceuticals set a new 52-week high after the company reported it entered into a definitive agreement with Johnson & Johnson to be acquired for $52.50 per share in cash.
Algernon Pharmaceuticals reported it has enrolled the first U.S. patient in its multinational Phase 2b/3 human study of Ifenprodil for use in treatment of SARS-CoV-2.
One highlight is ProMIS Neurosciences' development of a SARS CoV-2 antibody test.
The clinic will be integrated into the CloudMD EMR platform.
Shares of Mesoblast Ltd. traded 50% higher after the company reported that the U.S. FDA's Oncologic Drugs Advisory Committee voted nine to one in favor of remestemcel-L (RYONCIL™) for efficacy in children with steroid-refractory acute graft versus host disease.
Revive Therapeutics reported it signed a MOU with Attwill Medical Solutions Sterilflow to be a clinical packaging and distribution resource for its Phase 3 clinical trial of Bucillamine in COVID-19.
This development is a technical milestone for Revive Therapeutics and its drug delivery technology.
Shares of The Pennant Group reached a new 52-week high after the company reported a 12.1% increase in Q2/20 revenue and raised FY/20 adjusted EPS guidance by 34.2%.
Avivagen Inc. reported it achieved its first sale of OxC-beta™ Livestock in Brazil, the world's third largest livestock feed market.
Shares of Eyenovia Inc. set a new 52-week high after the firm reported it entered into an exclusive collaboration and license agreement with Arctic Vision to develop and market MicroPine and MicroLine in China and South Korea.
Seres Therapeutics shares traded 350% higher setting a new 52-week high after the firm reported positive topline results from its SER-109 Phase 3 ECOSPOR III study in recurrent C. difficile infection.
Dr. KSS, the founder and editor-in-chief of BioPub.co, compares the two drugs as potential treatments for C. difficile.
Independent financial analyst Matt Badiali examines five small companies poised to profit as digital health becomes mainstream during the coronavirus pandemic.
Algernon Pharmaceuticals reported that the first patient has been dosed in the Phase 2 human study of Ifenprodil for treatment of idiopathic pulmonary fibrosis and chronic cough.
Revive Therapeutics is now "finalizing agreements and aligning resources to initiate the Phase 3 clinical trial in September."
Shares of Denali Therapeutics reached a new 52-week high after the company reported plans to advance DNL151 in two separate late stage Parkinson's disease clinical studies with its partner Biogen.
These two CytoSorbents events are discussed in a Dawson James report.
Loop Insights' technology lacks the adoption challenges that app-based solutions face.
Shares of Fulgent Genetics traded 22% higher after the company reported it posted a record $17.1 million in Q2/20 revenue and completed a record 180,513 billable tests in the quarter.
Reliq Health Technologies reported it has entered into a new contract with Diversified Healthcare Partners to provide its iUGO Care platform to more than 50,000 patients in three U.S. states.
Revive Therapeutics' trial will test Bucillamine in patients with mild to moderate COVID-19.
Dr. KSS, the founder and editor-in-chief of BioPub.co, provides his investment thesis for a company that is promulgating the first new class of antibiotics in 30 years.
|"Momentum continues to build for VIV."|